The Federal Trade Commission's $1.2 billion settlement over a "pay for delay" deal is examined.
On Saturday, NewsHour Weekend revisits the backstory of the Federal Trade Commission's recent $1.2 billion settlement over a so-called "pay for delay" deal involving the wakefulness drug Provigil. Opponents like the FTC contend the deals delay generic medications to market and cost consumers billions in lost savings. But drug companies say that the deals help get generics to market by avoiding lengthy patent litigation. NewsHour's Megan Thompson reports in this updated segment.